Alzheimers disease (AD), also known as senile dementia, is caused by the deposition of amyloid beta (A ß) plaques in the brain and the formation of neurofibrillary tangles due to excessive phosphorylation of tau protein. It manifests as memory impairment, aphasia, loss of function, dementia, and impairment of visual spatial ability, often accompanied by changes in personality and behavior, seriou
Conditions
Interventions
Observation group :None
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
All
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1) Patients aged 50-90 years who meet the criteria for mild AD or AD related mild cognitive impairment are confirmed to be positive for amyloid protein through positron emission tomography (PET) or cerebrospinal fluid (CSF) A ß 1-42 measurement results. Mini Mental State Examination (MMSE): 22 <= MMSE <= 30. For patients with a Complementarity Determining Region (CDR) score of 0.5 or 1 for antibodies or T cell receptors, infusion of lencanavir monoclonal antibody should be administered to those who meet the above criteria.
Exclusion criteria
Exclusion criteria: 1) Patients with cognitive impairment caused by reasons other than AD, those with a history of transient ischemic attack (TIA), stroke, or epileptic seizures within the 12 months prior to screening, those with uncontrolled bleeding, those with serious other diseases, tumors, etc., should not use lencanavir monoclonal antibody.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infusion related reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| MMSE score; | — |
Countries
China
Contacts
Public Contactfuxiaoyan
Army Medical Center of PLA
Outcome results
None listed